Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Meprobamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meprobamate SCHEMBL15286 | 1.00 | LMNA (1.00) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL29045066 | 0.98 | LMNA (0.96) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL18703920 | 0.98 | LMNA (0.96) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL7583576 | 0.98 | LMNA (0.96) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL8913202 | 0.98 | LMNA (0.96) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL20545451 | 0.96 | LMNA (0.92) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL341321 | 0.96 | LMNA (0.92) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL8465286 | 0.94 | LMNA (0.89) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL8081512 | 0.92 | LMNA (0.85) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL8080895 | 0.91 | LMNA (0.82) | LMNAHSD17B10TSHRCYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101896161-A | Solid formulations of crystalline compounds | PURDUE RESEARCH FOUNDATION | 2010-11-24 | — | — | CN | disclosed |
| US-20100222311-A1 | SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-4727074-A | ANGINA PECTORIS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1988-02-23 | — | — | US | disclosed |
| US-4428887-A | Method of producing mono-substituted terminal diesters | MONSANTO COMPANY (US) | 1984-01-31 | — | — | US | disclosed |